Krystal Biotech, Inc. KRYS NASDAQ

Krystal Biotech, Inc. (KRYS) generated $200.87M in operating cash flow for fiscal year 2025. After capital expenditures of $11.95M, free cash flow was $188.91M.

Free cash flow margin was 48.5% of revenue. Cash conversion ratio was 0.98x, suggesting some earnings are non-cash.

Criteria supported by this page:

• HEALTH (100/100, Pass) — demonstrate the company can comfortably service its debt
• MOAT (66/100, Partial) — cash flow generation is present but not at levels indicating a wide moat
• INCOME (100/100) — Cash conversion ratio was 0.98x suggests some earnings are non-cash items

Overall SharesGrow Score: 85/100 with 4/7 criteria passed.